Margherita Melegari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Margherita Melegari has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Pier Paolo Scaglioni
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
4 shared publications Agnese Marucci
School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, MC, Italy
1 shared publicationAhmad T. Mansour
Department of pathology, St Elizabeth hospital, Edgewood, KY, USA
1 shared publication- Caterina Bartolacci
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
1 shared publication - Cristina Andreani
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
1 shared publication - Erica Villa
CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy
1 shared publication
Latest Publications
- Open Access
Thioredoxin Reductase 1 inhibition triggers ferroptosis in KRAS-independent lung cancers
Lung cancers that harbor wild type KRAS (KRAS-WT) represent a molecularly diverse subset of tumors that often lack targeted therapeutic options. Using synthesized gold(I)-based inhibitors, a multi-omics approach, and functional validation, we identified Thioredoxin reductase 1 (TXNRD1), encoding as a selective vulnerability in KRAS-WT and oncogenic KRAS mutant (KM)-independent lung cancer (LC). Mechanistically, TRXR1 blockade induces ferroptosis through glutathione depletion, lipid reactive oxygen species (ROS) accumulation, and HMOX1-dependent iron overload in KRAS-WT LC both in vitro and in vivo. Furthermore, while KM LC cells are intrinsically resistant to TRXR1 inhibition, KMLC cells that acquire resistance to KRAS inhibitors (KRASi) undergo a redox shift that renders them sensitive to TRXR1 inhibition, uncovering a potential novel therapeutic vulnerability in KRASi-refractory tumors. These findings establish TRXR1 as a targetable redox checkpoint in KRAS-WT and KRASi-resistant lung cancers and support further development of TRXR1 inhibitors.
Open AccessThioredoxin Reductase 1 inhibition triggers ferroptosis in KRAS-independent lung cancers
Lung cancers that harbor wild type KRAS (KRAS-WT) represent a molecularly diverse subset of tumors that often lack targeted therapeutic options. Using synthesized gold(I)-based inhibitors, a multi-omics approach, and functional validation, we identified Thioredoxin reductase 1 (TXNRD1), encoding as a selective vulnerability in KRAS-WT and oncogenic KRAS mutant (KM)-independent lung cancer (LC). Mechanistically, TRXR1 blockade induces ferroptosis through glutathione depletion, lipid reactive oxygen species (ROS) accumulation, and HMOX1-dependent iron overload in KRAS-WT LC both in vitro and in vivo. Furthermore, while KM LC cells are intrinsically resistant to TRXR1 inhibition, KMLC cells that acquire resistance to KRAS inhibitors (KRASi) undergo a redox shift that renders them sensitive to TRXR1 inhibition, uncovering a potential novel therapeutic vulnerability in KRASi-refractory tumors. These findings establish TRXR1 as a targetable redox checkpoint in KRAS-WT and KRASi-resistant lung cancers and support further development of TRXR1 inhibitors.
- Open Access
PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer
- 1 October 1997
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 12 (9-10) , S354-S369
Nucleic acid‐based antiviral and gene therapy of chronic hepatitis B infection
Persistent hepatitis B virus (HBV) infection often leads to the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma. There is a need to develop new antiviral approaches for the treatment of this disease. We have explored various nucleic acid-based strategies designed to inhibit HBV replication including: the use of antisense RNA and DNA constructs, DNA-based immunization techniques to stimulate broad-based cellular immune responses with particular emphasis on the generation of cytotoxic lymphocyte (CTL) activity to viral structural proteins, hammerhead ribozymes to cleave HBV pregenomic RNA in vitro and dominant negative HBV core mutant proteins as inhibitors of nucleocapsid formation within cells. In order to optimize these antiviral effects, various novel expression vectors have been developed to deliver such DNA constructs to cells. For example, adenoviral vectors carrying genes that encode for dominant negative proteins have been employed to transfect hepatocytes in vitro and in vivo. In addition, plasmid vectors have been produced to promote expression of HBV structural genes following injection into muscle cells as a means to stimulate the host's cellular and humoral immune response in the context of histocompatibility antigen (HLA) class I and II antigen presentation. These experimental approaches may have important implications for the generation of efficient antiviral effects during chronic HBV infection.
- 1 October 1997
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 12 (9-10) , S354-S369
Nucleic acid‐based antiviral and gene therapy of chronic hepatitis B infection
Persistent hepatitis B virus (HBV) infection often leads to the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma. There is a need to develop new antiviral approaches for the treatment of this disease. We have explored various nucleic acid-based strategies designed to inhibit HBV replication including: the use of antisense RNA and DNA constructs, DNA-based immunization techniques to stimulate broad-based cellular immune responses with particular emphasis on the generation of cytotoxic lymphocyte (CTL) activity to viral structural proteins, hammerhead ribozymes to cleave HBV pregenomic RNA in vitro and dominant negative HBV core mutant proteins as inhibitors of nucleocapsid formation within cells. In order to optimize these antiviral effects, various novel expression vectors have been developed to deliver such DNA constructs to cells. For example, adenoviral vectors carrying genes that encode for dominant negative proteins have been employed to transfect hepatocytes in vitro and in vivo. In addition, plasmid vectors have been produced to promote expression of HBV structural genes following injection into muscle cells as a means to stimulate the host's cellular and humoral immune response in the context of histocompatibility antigen (HLA) class I and II antigen presentation. These experimental approaches may have important implications for the generation of efficient antiviral effects during chronic HBV infection.
- 1 September 1991
- Published by Elsevier in Journal of Hepatology
- Vol. 13 (2) , 187-191
Conserved core protein sequences in hepatitis B virus infected patients without anti-HBc
- 1 September 1991
- Published by Elsevier in Journal of Hepatology
- Vol. 13 (2) , 187-191
Conserved core protein sequences in hepatitis B virus infected patients without anti-HBc